Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$79.91

-0.86 (-1.06%)

, AGN

Allergan

$147.13

-2.27 (-1.52%)

04:55
03/28/19
03/28
04:55
03/28/19
04:55

Academy of Managed Care Pharmacy to hold annual meeting

Managed Care & Specialty Pharmacy Annual Meeting 2019 will be held in San Diego, CA on March 25-28.

ABBV

AbbVie

$79.91

-0.86 (-1.06%)

AGN

Allergan

$147.13

-2.27 (-1.52%)

AMRN

Amarin

$18.08

0.56 (3.20%)

AZN

AstraZeneca

$42.64

-0.3 (-0.70%)

BAYRY

Bayer

$0.00

(0.00%)

BIIB

Biogen

$229.85

-3.13 (-1.34%)

NVO

Novo Nordisk

$52.13

0.19 (0.37%)

LLY

Eli Lilly

$128.72

-2.35 (-1.79%)

PODD

Insulet

$93.38

-3.33 (-3.44%)

INSM

Insmed

$27.59

-0.41 (-1.46%)

GILD

Gilead

$63.67

-0.58 (-0.90%)

TEVA

Teva

$16.00

0.09 (0.57%)

TSRO

Tesaro

$0.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

SYNH

Syneos Health

$50.07

-0.42 (-0.83%)

SUPN

Supernus

$34.37

0.18 (0.53%)

CVS

CVS Health

$54.03

-1.37 (-2.47%)

SNSS

Sunesis

$1.02

-0.17 (-14.29%)

AIPT

Precision Therapeutics

$0.76

-0.0414 (-5.16%)

CHRS

Coherus Biosciences

$13.51

-0.59 (-4.18%)

CELG

Celgene

$88.78

-0.42 (-0.47%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

  • 29

    Mar

  • 01

    Apr

  • 08

    Apr

  • 12

    Apr

  • 24

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 07

    May

  • 18

    May

  • 27

    Jun

  • 03

    Sep

  • 04

    Nov

  • 27

    Mar

ABBV AbbVie
$79.91

-0.86 (-1.06%)

03/13/19
PIPR
03/13/19
NO CHANGE
Target $90
PIPR
Neutral
Piper dermatologist survey offers 'good news/bad news' for AbbVie
Piper Jaffray analyst Christopher Raymond views his firm's survey of 101 U.S. dermatologists as "good news/bad news" for AbbVie's dermatology franchise. On the positive side, due to both AbbVie's "significant goodwill" as well as risankizumab's superior clinical profile, dermatologists indicate "significant uptake" of the drug once approved, Raymond tells investors in a research note. On the negative side, Humira continues to lose market share to newer biologics like anti-IL-17s and approved anti-IL-23s at a "rapid pace" that may be accelerated by cannibalization at the hands of risankizumab, adds the analyst. Following the surgery, Raymond remains comfortable with his below-consensus AbbVie revenue estimates this year and next. He keeps a Neutral rating on the shares with a $90 price target.
03/25/19
ARGS
03/25/19
DOWNGRADE
ARGS
Hold
AbbVie downgraded to Hold from Buy at Argus
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
03/25/19
03/25/19
DOWNGRADE

Hold
AbbVie downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded AbbVie to Hold, saying its flagship program Humira "no longer looks invulnerable to competition from biosimilars in Europe and other overseas markets." The analyst notes that Humira is also faced with "indirect competition from newer drugs that have an alternative mechanism of action" compared to Humira's anti-TNF class. Toung further cites AbbVie's clinical setback with Venclexta, which highlights the risks for the company as it develops a pipeline aimed to offset the expected decline in Humira sales.
AGN Allergan
$147.13

-2.27 (-1.52%)

03/22/19
ADAM
03/22/19
NO CHANGE
ADAM
Buy
Breast implant panel documents in-line with expectations, says Canaccord
Canaccord analyst Kyle Rose maintains his Buy rating on Sientra (SIEN) following the release of briefing documents ahead of next week's FDA panel meeting to review a range of topics related to the long-term benefits and risks of breast implants, stating that the documents appear to be in-line with expectations and do not appear to raise any materially new or concerning questions or data. However, given the warning letters sent this week to Sientra and J&J's (JNJ) Mentor unit, Rose said he expects the FDA to "take a strong tone" during the panel about the responsibility to support the collection and analysis of relevant safety and efficacy clinical data. Other makers of breast implants include Allergan (AGN) and Establishment Labs (ESTA).
03/20/19
PIPR
03/20/19
NO CHANGE
Target $161
PIPR
Neutral
Piper Jaffray questions value creation of potential Allergan break up
There is some thought among investors that a separation of Allergan (AGN) into its global medical aesthetics business and its pharma business should unlock significant value, Piper Jaffray analyst David Amsellem tells investors in a research note titled "A Break Up Is By No Means A Panacea; Staying Cautious." The analyst's questions this thinking, saying this course of action "cannot paper over the challenges" facing both businesses. His sum-of-the-parts analyses suggest that a break-up "would confer only modest value creation." And even that may not be sustainable as competitive challenges surrounding Botox and losses of exclusivities beyond Restasis come into focus, contends Amsellem. "Simply put, a separation in and of itself is not the transformative change we would be looking for," says the analyst. He reiterates a Neutral rating on Allergan with a $161 price target.
03/19/19
RHCO
03/19/19
INITIATION
Target $29
RHCO
Buy
Evolus assumed with a Buy at SunTrust
SunTrust transferred coverage of Evolus (EOLS) to analyst Gregg Gilbert, who established a Buy rating and $29 price target on the stock. The analyst cites the company preparing to enter the US botulinum toxin market, adding that with Jeuveau "de-risked from a regulatory standpoint following FDA approval", investor focus will shift to the near-term launch of "frictionless alternative" to market-leading Botox from Allergan (AGN). Gilbert contends that Evolus could carve a "nice slice of this rapidly-growing market".
03/19/19
RHCO
03/19/19
INITIATION
Target $178
RHCO
Buy
Allergan initiated with a Buy at SunTrust
SunTrust analyst Gregg Gilbert initiated Allegran with a Buy rating and a price target of $178. The analyst states that while the stock has been underperforming, he also sees it as inexpensive with valuation reflecting competitive threats to franchises. Gilbert believes that Allergan offers an "attractive return potential over the next 12+ months if the company continues to meet or exceed its financial targets".
AMRN Amarin
$18.08

0.56 (3.20%)

02/28/19
HCWC
02/28/19
NO CHANGE
Target $51
HCWC
Buy
Amarin offered window into Vascepa revenue momentum, says H.C. Wainwright
On yesterday's call, Amarin shared a few data points of Vascepa's growth post Reduce-IT results that offered a glimpse of the revenue momentum, and "may be a forbearer of what is to come," H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst highlights the 32%-33% prescription increase in the Q4 compared to the same period in 2017. Further, he expects Amarin to promote Vascepa with a greater degree of freedom that should further accelerate the adoption. Fein reiterates a Buy rating on Amarin with a $51 price target.
03/21/19
STFL
03/21/19
INITIATION
Target $27
STFL
Buy
Stifel starts Amarin with Buy rating, sees 'robust' growth for Vascepa
Stifel analyst Derek Archila initiated coverage of Amarin with a Buy rating and $27 price target. The shares closed the trading day down 25c to $18.76 but are trading up $1.08 to $19.84 in the after-hours market. Vascepa's Reduce-IT study results are "impressive" and a physician survey shows they will "most certainly lead to robust growth," likely above management's 2019 guidance, Archila tells investors in a research note. The analyst adds, though, that his call "runs counter to the prevailing sentiment" that Amarin will be acquired in the near term. He believes the outcome of an FDA advisory committee discussing the Reduce-IT results and controversies around them will be needed before a takeout can occur. Nonetheless, his due diligence with regulatory experts get him comfortable with an FDA approval for a Vascepa label expansion to include reduction in cardiovascular risk based on the Reduce-IT results in early 2020. This should effectively increase the drug's addressable market size by a factor of 20, says Archila. The analyst used a "blended methodology given the takeout premium in the stock" to arrive at a $27 target price.
03/21/19
STFL
03/21/19
INITIATION
Target $27
STFL
Buy
Amarin initiated with a Buy at Stifel
Stifel analyst Derek Archila started Amarin with a Buy rating and $27 price target.
03/13/19
SBSH
03/13/19
NO CHANGE
SBSH
Amarin's Reduce-It results viewed favorably by doctors, says Citi
Citi analyst Joel Beatty conducted a survey of 325 U.S. physicians to assess views related to Amarin's Vascepa. Of the doctors that were "very familiar" with the Reduce-It results, 84% provided positive comments regarding the study, Beatty tells investors in a research note. Further, prior authorization requirements are seen as a "major barrier" to Vascepa use, the analyst adds. He keeps a Buy rating on Amarin.
AZN AstraZeneca
$42.64

-0.3 (-0.70%)

03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
02/05/19
EXAN
02/05/19
INITIATION
EXAN
Outperform
AstraZeneca initiated with an Outperform at Exane BNP Paribas
02/05/19
02/05/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AIG (AIG) initiated with a Neutral at Credit Suisse. 2. Box (BOX) initiated with a Buy at Goldman Sachs. 3. Rocket Pharmaceuticals (RCKT) initiated with an Outperform at Oppenheimer. 4. AstraZeneca (AZN) initiated with an Outperform at Exane BNP Paribas. 5. MercadoLibre (MELI) resumed with a Buy at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BAYRY Bayer
$0.00

(0.00%)

01/02/19
JPMS
01/02/19
DOWNGRADE
JPMS
Neutral
Bayer downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Richard Vosser downgraded Bayer to Neutral and lowered his price target for the shares to EUR 70 from EUR 100. The analyst believes 2019 will be another "messy year" for the company.
03/21/19
03/21/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Market Perform from Outperform at Wells Fargo after the company reported the failure of two phase 3 trials for a potential treatment of Alzheimer's disease. 2. Magna (MGA) downgraded to Market Perform from Outperform at BMO Capital with analyst Peter Sklar noting BMW's (BMWYY) lowered 2019 earnings guidance on numerous headwinds reflects how difficult it is for auto manufacturers to grow earnings during a period of flat to declining vehicle production volumes. 3. Munich Re (MURGY) downgraded to Hold from Buy at Jefferies with analyst Philip Kett saying he believes the recent rally leaves less room for valuation upside. 4. Nufarm (NFRMY) downgraded to Neutral from Overweight at JPMorgan with analyst Donald Carducci noting glyphosate is becoming a concern for Bayer (BAYRY) due to a recent U.S. case progressing to phase two. 5. Micron (MU) downgraded to Sell from Neutral at Citi with analyst Christopher Danely saying Micronis trying its best but "you can't swim against a tsunami". This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BIIB Biogen
$229.85

-3.13 (-1.34%)

03/22/19
03/22/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PPG (PPG) downgraded to Underweight from Neutral at JPMorgan with analyst Jeffrey Zekauskas saying PPG shares have been drifting higher in 2019 as the market continues to prefer higher quality and less cyclical materials companies, however general economic business conditions are "arguably weaker than they have been because of decreased rates of economic growth in China and in Europe." 2. Sherwin-Williams (SHW) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas citing valuation. 3. Booking Holdings (BKNG) downgraded to Neutral from Outperform at Wedbush with analyst James Hardiman stating that he believes the company's dominant position in Europe will be favorable in the long term, but is likely to represent a liability in 2019 as it is could amplify risks of earnings revisions and multiple compression. 4. Biogen (BIIB) downgraded to Underweight from Overweight at Morgan Stanley with analyst Matthew Harrison citing the failure of two Alzheimer's disease trials and noting that his optimism on Alzheimer's was "completely wrong." 5. Lululemon (LULU) downgraded to Neutral from Outperform at Wedbush with analyst Jen Redding saying that while she continues to see lululemon as best in class among specialty retailers, she is moving to the sidelines in anticipation of potentially less margin upside ahead, based on insights from proprietary data products. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
HCWC
03/25/19
NO CHANGE
Target $300
HCWC
Buy
Biogen price target lowered to $300 from $363 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Biogen to $300 from $363 after the company and Eisai decided to stop clinical trials of aducanumab based on the futility results of the interim analysis of the Phase 3 trials. Investor focus will likely now shift to the pipeline growth and defense of Biogen's multiple sclerosis franchise, Fein tells investors in a research note. He thinks Spinraza should continue to drive revenue growth in the near-term and believes Biogen has sufficient financial means to continue investing in the pipeline to support the long-term growth of the company. The analyst keeps a Buy rating on the shares.
03/25/19
RBCM
03/25/19
NO CHANGE
Target $236
RBCM
Sector Perform
Biogen price target lowered to $236 from $318 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Biogen to $236 and kept his Sector Perform rating after the failure of its two Alzheimer's disease trials. The analyst notes that investors will now shift their focus towards the upcoming IP developments risks for Tecfidera and potential competition to its Spinraza, but also sees "few near-term opportunities to generate enthusiasm" for Biogen's ability to "fill the gap left by aducanumab and out-year loss of base business revenues."
03/26/19
PIPR
03/26/19
NO CHANGE
Target $280
PIPR
Overweight
Piper continues to recommend Biogen shares after deeper dive on BIIB067
Piper Jaffray analyst Christopher Raymond continues to recommend Biogen shares after a deeper dive on BIIB067, an anti-sense oligonucleotide targeting SOD1 for the treatment of SOD1-amyotrophic lateral sclerosis. With the recent discontinuation of aducanumab in mild Alzheimer's disease, the company's amyotrophic lateral sclerosis anti-sense oligonucleotide programs could help dispel the notion that Biogen has no pipeline, Raymond tells investors in a research note. He thinks the BIIB067 and BIIB078 programs could add $10 and $15, respectively, to the stock if successful. Raymond keeps an Overweight rating on Biogen with a $280 price target. The stock closed yesterday up $3.55 to $220.26.
NVO Novo Nordisk
$52.13

0.19 (0.37%)

01/23/19
OTRG
01/23/19
NO CHANGE
OTRG
Novo Nordisk Ozempic script growth accelerates, says OTR Global
OTR Global's checks indicate Novo Nordisk's Ozempic script growth accelerated during Q4.
02/01/19
MSCO
02/01/19
INITIATION
MSCO
Equal Weight
Novo Nordisk reinstated with an Equal Weight at Morgan Stanley
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
01/29/19
EXAN
01/29/19
INITIATION
EXAN
Outperform
Novo Nordisk reinstated with an Outperform at Exane BNP Paribas
LLY Eli Lilly
$128.72

-2.35 (-1.79%)

03/20/19
UBSW
03/20/19
INITIATION
Target $140
UBSW
Buy
Eli Lilly resumed with a Buy at UBS
UBS analyst Navin Jacob resumed coverage of Eli Lilly with a Buy rating, also raising his price target to $140 from $131. The analyst says the consensus on the stock does not fully value the "strength & growth" of the company's Human Health business, which he expects to become more apparent following the Elanco (ELAN) spinoff. Jacob adds that Eli Lilly should be able to achieve its 2020 operating margin guidance of over 31% amid impressive Trulicity growth and strong volumes for Jardiance.
03/21/19
BMOC
03/21/19
NO CHANGE
BMOC
Outperform
Biogen Alzheimer's news incrementally negative for Eli Lilly, says BMO Capital
BMO Capital analyst Alex Arfaei said Biogen's (BIIB) report of the failure of aducanumab weakens, if not removes, a potential source of upside for Eli Lilly (LLY), which has an "aducanumab like" antibody in phase 2 development for Alzheimer's. However, he noted that consensus expectations for Eli Lilly's N3pG "were low, rightfully so" and he sees Alzheimer's continuing to be a highly challenging area of drug development. Arfaei has an Outperform rating on Eli Lilly shares.
03/12/19
JPMS
03/12/19
INITIATION
Target $140
JPMS
Overweight
JPMorgan reinstates Eli Lilly at Overweight, adds to Analyst Focus List
JPMorgan analyst Chris Schott reinstated coverage of Eli Lilly with an Overweight rating and $140 price target. He also added the shares to his firm's Analyst Focus List. The analyst continues to see Lilly as the best positioned of his large-cap names based on a combination of "healthy" core product growth, a "growing" portfolio of new launches and next-generation pipeline assets, a "significant margin expansion story," and "several sources of upside to near- and long-term numbers." Schott expects Eli Lilly to generate 6%-8% sales growth and mid-teens annual earnings growth through much of the decade. The stock represents a top pick in his coverage universe.
01/25/19
PIPR
01/25/19
NO CHANGE
PIPR
Report that CVS excluded Amgen's Aimovig 'greatly exaggerated,' says Piper
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $220 price target on Amgen (AMGN) following a Reuters report from earlier on Friday which stated that CVS (CVS) has excluded Amgen's Aimovig from its formulary. The analyst called the report "Friday afternoon clickbait" and noted that while CVS currently provides preferred status to Teva's (TEVA) Ajovy and Eli Lilly's (LLY) Emgality, this was made public in late 2018. In a check with management, Raymond found out the decision only encompasses about one-third of CVS network, that CVS is actively working to improve this access, and that 70% of commercial migraine patients have contracted access to Aimovig. Raymond concluded that this was "not something to worry about" in his view, and did not change his Q4, FY19, or FY20 estimates on Aimovig. In Friday trading, shares of Amgen were down just over 1% to $198.77.
PODD Insulet
$93.38

-3.33 (-3.44%)

02/26/19
ADAM
02/26/19
NO CHANGE
Target $100
ADAM
Buy
Insulet long-term story keeps getting better, says Canaccord
Canaccord analyst Kyle Rose said Insulet reported solid Q4 results, but guidance came in below Street expectations. The analyst said he expected that to happen and modeled for it, but he sees a compelling new product cycle in Dash. Rose, who sees the company in the early stages of a transformative 24-month period that will see meaningful global share gains, reiterated his Buy rating and $100 price target on Insulet shares.
02/19/19
ADAM
02/19/19
NO CHANGE
Target $100
ADAM
Buy
Insulet price target raised to $100 from $90 at Canaccord
Canaccord analyst Kyle Rose raised his price target on Insulet to $100 from $90 as he believes the company is in the early stages of a transformative 24-month period that will see meaningful global share gains and significant margin expansion. He also updated his model ahead of Q4 results to reflect a more conservative revenue ramp for 2019, which he believes positions the company as a beat-and-raise story going forward. Rose reiterated his Buy rating on Insulet shares.
01/07/19
PIPR
01/07/19
NO CHANGE
Target $106
PIPR
Overweight
Insulet 'in good hands' with new CFO Wayde McMillan, says Piper Jaffray
Following news that Insulet has named Wayde McMillan as its new CFO, Piper Jaffray analyst JP McKim said that while outgoing CFO Michael Levitz will "certainly be missed," as he has been "crucial" to the company's profitable growth over the last four years, he feels that the company is in "good hands" with McMillan, who brings 20 years of relevant experience as well as M&A experience. McKim, who reiterates an Overweight rating and $106 price target on Insulet shares, tells investors in a research note that "now is as good a time as any" for a CFO transition.
02/26/19
BARD
02/26/19
NO CHANGE
Target $118
BARD
Outperform
Insulet weakness a buying opportunity, says Baird
Baird analyst Jeff Johnson said Q4 results for Insulet were positive, but the shares will likely open lower as the guidance was slightly below Street expectations and implies decelerating growth over the next few quarters. The analyst said he would be a buyer on the expected weakness, as he sees a credible path to accelerating share gains for the company upon launch of Horizon later this year. Johnson reiterated his Outperform rating and $118 price target on Insulet shares.
INSM Insmed
$27.59

-0.41 (-1.46%)

02/15/19
JMPS
02/15/19
UPGRADE
Target $40
JMPS
Outperform
Insmed upgraded to Outperform following Arikayce survey at JMP Securities
As previously reported, JMP Securities analyst Liisa Bayko upgraded Insmed to Outperform from Market Perform, stating that her survey of "early adopters" of Arikayce shows a high rate of utilization with a favorable early experience that is encouraging more usage. This suggests Arikayce will beat 2019 consensus, contends Bayko, who raised her 2019 Arikayce revenue estimates. She set a $40 price target on Insmed shares.
03/08/19
ADAM
03/08/19
NO CHANGE
Target $44
ADAM
Buy
Insmed price target raised to $44 from $32 at Canaccord
Canaccord analyst Dewey Steadman raised his price target on Insmed to $44 from $32 following Q4 results. The analyst was impressed with the Arikayce uptake to-date and he thinks its initial guidance leaves room for a beat once Medicare dynamics are fully understood. He also sees continued growth in the Arikayce franchise and its pulmonary pipeline provides additional upside optionality. Steadman reiterated his Buy rating on Insmed shares.
02/15/19
JMPS
02/15/19
UPGRADE
JMPS
Outperform
Insmed upgraded to Outperform from Market Perform at JMP Securities
03/26/19
STFL
03/26/19
NO CHANGE
Target $43
STFL
Buy
Pulmonologist call reinforces Stifel view of upside for Insmed
After hosting a conference call with two key opinion leader pulmonologists to discuss the rollout of Arikayce, Stifel analyst Adam Walsh said their feedback suggested the strong start for the drug was not the result of a "bolus" of patients awaiting approval and noted that both doctors said their new-patient starts remain steady. While it "remains early days in the launch," the call with the doctors reinforced his belief that Insmed's Arikayce guidance is likely conservative, Walsh tells investors. He keeps a Buy rating and $43 price target on Insmed shares.
GILD Gilead
$63.67

-0.58 (-0.90%)

03/07/19
PIPR
03/07/19
NO CHANGE
Target $75
PIPR
Neutral
Gilead Truvada conversion still looks challenging, says Piper Jaffray
Gilead Sciences reported positive data from the Phase III Discover trial and the efficacy data demonstrated non-inferiority of Descovy to Truvada for HIV pre-exposure prophylaxis, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst, however, believes the numerical improvements appear small and wonders if a year will be enough time to convert the majority of a $2.6B Truvada U.S. sales franchise prior to generic entry in 2021 In order for this conversion to be "exceedingly" successful, the safety advantage needs to be "dramatic" given the anticipated low price of generic Truvada, says Van Buren. He's still uncertain as to how well it will go and keeps a Neutral rating on Gilead with a $75 price target.
03/17/19
PIPR
03/17/19
NO CHANGE
Target $75
PIPR
Neutral
Gilead HIV drugs' price increase 30% lower than prior years, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren notes that as expected, effective March 16th, Gilead raised list prices of the company's top 6 selling HIV antiviral drugs by 4.9% which includes Atripla, Biktarvy, Descovy, Genvoya, Odefsey, and Truvada. Notably, the price increases were roughly 30% lower than what has been observed in prior years and likely reflects the recent increasing pressure on drug pricing, he contends. The analyst also notes that these increases are well below the high single digit year over year price increases that have been observed with other companies, which Gilead can afford due to strong volume growth of its next generation TAF-based regimens. Van Buren reiterates a Neutral rating and $75 price target on the shares.
03/15/19
03/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simmons First National (SFNC) initiated with a Buy at DA Davidson. 2. Amgen (AMGN) and Gilead (GILD) initiated with an Outperform at BMO Capital. 3. Rocket Pharmaceuticals (RCKT) initiated with a Buy at BofA/Merrill. 4. Urovant Sciences (UROV) initiated with a Buy at SunTrust. 5. Spectrum (SPPI) assumed with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/19
BMOC
03/14/19
INITIATION
Target $78
BMOC
Outperform
Gilead initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini started Gilead Sciences with an Outperform rating and $78 price target. The company's HIV franchise should remain dominant for at least the next several years while a growing dividend and continued buybacks "provide investors with a baseline return," Luchini tells investors in a research note. Further, the analyst believes current levels provide an attractive entry point.
TEVA Teva
$16.00

0.09 (0.57%)

03/13/19
WELS
03/13/19
NO CHANGE
Target $68
WELS
Market Perform
Wells says generic risk, not Purdue news, bringing down Emergent shares
Wells Fargo analyst David Maris "completely" disagrees with the view that shares of Emergent BioSolutions (EBS) are weak today on news of Purdue Pharma's nalmefene injection receiving fast track designation from the FDA. Maris notes that none of his clients have raised this as a potential issue and that, as an injection, Purdue's pproduct is not comparable to Emergent's nasal naloxone. An injection is not practical for the emergency medical technician and at home market, where most of Narcan is used, Maris tells investors in a research note. For example, Amphastar (AMPH) is a leader in the injectable market, and the vast majority of its use is in the hospital setting, the analyst points out. Rather, Maris attributes the recent selloff in Emergent BioSolutions to worries about the potential introduction of a generic version of Narcan. Teva (TEVA) has had a tentative approval for generic Narcan for some time, and its 30 month stay is over today, meaning that Teva could launch at risk from this point forward, Maris writes. As of now, there is no clear indication whether Teva will launch or not, he adds. While the analyst is not expecting an at-risk Narcan launch, he believes the risk of such an event is largely reflected in the shares given today's decline. Nonetheless, Maris keeps a Market Perform rating on Emergent with a $68 price target. The stock in afternoon trading is down 9%, or $4.98, to $52.00.
03/19/19
RHCO
03/19/19
INITIATION
Target $17
RHCO
Hold
Teva initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert initiated Teva with a Hold rating and a price target of $17, saying that while the new CEO Kare Schultz led a cost base restructuring effort and trying to turn around the U.S. generics business, those positive are likely factored into the stock price. The analyst adds that the company's recent delay in expecting to achieve its deleveraging target "may make existing holders anxious and potential holders more patient."
03/07/19
03/07/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Five Below (FIVE) initiated with an Outperform at Oppenheimer. 2. Teva (TEVA) reinstated with a Buy at UBS. 3. Chiasma (CHMA) initiated with an Overweight at Cantor Fitzgerald. 4. Monster Beverage (MNST) and Constellation Brands (STZ) were initiated with an Outperform at Credit Suisse, while Procter & Gamble (PG), Coca-Cola (KO), and Church & Dwight (CHD) were initiated with a Neutral, and PepsiCo (PEP), Colgate-Palmolive (CL), and Clorox (CLX) initiated with an Underperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/07/19
UBSW
03/07/19
INITIATION
Target $22
UBSW
Buy
Teva reinstated with a Buy at UBS
UBS analyst Navin Jacob reinstated coverage of Teva Pharmaceutical with a Buy rating and $22 price target. The U.S. generic industry is on a path to recovery, Jacob tells investors in a research note, citing his firm's generic price erosion tracker data. The analyst sees 30% potential upside and views Teva's 2019 guidance as a "hiccup."
TSRO Tesaro
$0.00

(0.00%)

12/10/18
LEHM
12/10/18
DOWNGRADE
Target $75
LEHM
Equal Weight
Tesaro downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Tesaro (TSRO) to Equal Weight citing the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $48.
12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/05/18
CANT
12/05/18
DOWNGRADE
Target $75
CANT
Neutral
Tesaro downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young downgraded Tesaro (TSRO) to Neutral to reflect the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $68.
DNA Bought by RHHBY
$0.00

(0.00%)

SYNH Syneos Health
$50.07

-0.42 (-0.83%)

01/08/19
BARD
01/08/19
NO CHANGE
Target $60
BARD
Outperform
Syneos Health designated as Fresh Pick and Best Idea for 2019 at Baird
Baird analyst Eric Coldwell designated Syneos Health as a Fresh Pick and calls it a Best Idea for 2019. The analyst remains comfortable with his 2019 estimates and overall thesis and he said several sell-side peers may have adequately lowered expectations into guidance, improving the setup for the shares. Coldwell reiterated his Outperform rating and $60 price target on Syneos Health shares.
03/19/19
WBLR
03/19/19
NO CHANGE
WBLR
Outperform
Syneos Health discount to group 'seems excessive,' says William Blair
William Blair analyst John Kreger noted that Syneos Health released fourth quarter results that were well ahead of his expectations and gave initial 2019 guidance that was also modestly ahead of his forecasts following a delay that was prompted by an SEC investigation notice. While he believes a modest discount to the peer group is warranted, given the SEC investigation and the market view that commercial deserves a lower multiple, Kreger thinks the stock's current discount "seems excessive." He reiterates an Outperform rating on Syneos Health shares.
03/19/19
UBSW
03/19/19
DOWNGRADE
UBSW
Neutral
Syneos Health downgraded to Neutral from Buy at UBS
03/19/19
UBSW
03/19/19
DOWNGRADE
Target $55
UBSW
Neutral
Syneos Health downgraded to Neutral on SEC probe risks at UBS
As previously reported, UBS analyst Daniel Brennan downgraded Syneos Health to Neutral from Buy as the stock's implied discount versus peers has narrowed to less than 5% despite higher risks given an ongoing SEC investigation and material weaknesses now part of the 10K. The "distraction and optics" of an SEC investigation creates an opening for competitors, contends Brennan. He keeps a $55 price target on Syneos Health shares.
SUPN Supernus
$34.37

0.18 (0.53%)

01/31/19
01/31/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Gordon Haskett. 2. Teladoc (TDOC) initiated with a Buy at Berenberg. 3. Intercept (ICPT) initiated with an Outperform at Credit Suisse. 4. Recro Pharma (REPH), BioDelivery Sciences (BDSI), and Supernus (SUPN) were assumed with a Buy at Janney Montgomery Scott. 5. Green Thumb Industries (GTBIF) initiated with a Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/19
JANY
01/31/19
INITIATION
Target $55
JANY
Buy
Supernus assumed with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Esther Hong assumed coverage of Supernus with a Buy rating and $55 fair value estimate.
01/28/19
RILY
01/28/19
NO CHANGE
Target $65
RILY
Buy
Supernus added to Alpha Generator list at B. Riley FBR
B. Riley FBR analyst David Buck added Supernus Pharmaceuticals to his firm's Alpha Generator list and reiterates a Buy rating on the shares with a $65 price target. He expects continued growth for Trokendi XR despite new entrants in the migraine category.
01/16/19
PIPR
01/16/19
NO CHANGE
Target $44
PIPR
Neutral
Piper says Supernus shares not attractive after 'mixed' psychiatrist survey
Piper Jaffray analyst David Amsellem says his firm conducted a "brief" survey of 27 psychiatrists with the goal of gauging perceptions of the potential role of Supernus Pharmaceuticals' (SUPN) SPN-812 in pediatric and adolescent attention-deficit/hyperactivity disorder. While some of the feedback was suggestive of a meaningful role for SPN-812 in the broader ADHD treatment armamentarium, and as a potential alternative to Eli Lilly's (LLY) Strattera and even stimulants in some cases, "this was far from a consensus view," Amsellem tells investors in a research note. There was equally as much feedback suggesting a more limited role for SPN-812, adds the analyst. Taken together, Amsellem remains concerned about the extent to which the payer landscape for SPN-812 will be restrictive. He views the survey results as mixed for Supernus and says the stock is not attractive at these levels. The analyst reiterates a Neutral rating on the name with a $44 price target.
CVS CVS Health
$54.03

-1.37 (-2.47%)

03/27/19
WELS
03/27/19
NO CHANGE
WELS
Centene might internalize WellCare PBM business, says Wells Fargo
Wells Fargo analyst Peter Costa notes that Centene (CNC) announced plans to acquire WellCare (WCG) for $120 in cash and 3.38 shares of Centene for each share of WellCare. The analyst expects Centene to eventually internalize WellCare's pharmacy benefit management (PBM) business, which would likely be another blow to CVS (CVS), WellCare's current PBM. Centene currently has some of its PBM business with CVS and is bringing that business in-house to its own internal PBM, while WellCare is planning to rebid its PBM contract this year, he notes, adding that this merger would likely mean that contract rebid may not occur and that WellCare would more likely move its estimated $15B-$20B in pharmacy spend away from CVS to Centene for 2021.
03/21/19
RAJA
03/21/19
UPGRADE
Target $8
RAJA
Outperform
Raymond James upgrades Diplomat Pharmacy, sees number of potential suitors
Raymond James analyst John Ransom upgraded Diplomat Pharmacy (DPLO) to Outperform from Market Perform with an $8 price target. The stock closed yesterday up 14c to $5.86. Following the 56% share decline since the February earnings delay, Diplomat would represent value to a strategic buyer, Ransom tells investor in a research note. The analyst sees a number of potential buyers that would "covet" Diplomat Pharmacy's infusion franchise and could fold its large mail order business into an existing platform, including UnitedHealth (UNH), Cigna (CI), CVS Health (CVS), Anthem (ANTM) and Centene (CNC). Ransom thinks Diplomat's current fundamentals should motivate its board to step up its assessment of strategic options. He believes the company's collection of assets are underappreciated at current valuation levels.
03/13/19
03/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. CVS Health (CVS) initiated with an Outperform at Bernstein. 2. Rhythm Pharmaceuticals (RYTM) initiated with a Buy at Ladenburg. 3. Solaris Oilfield (SOI) initiated with a Buy at B. Riley FBR. 4. Americold Realty Trust (COLD) initiated with a Buy at Berenberg. 5. Cheniere Energy (LNG) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/19
03/13/19
INITIATION
Target $76

Outperform
Bernstein bullish on CVS Health, initiates coverage with an Outperform
As previously reported, Bernstein analyst Lance Wilkes started coverage of CVS Health with an Outperform rating and $76 price target. The analyst believes the current stock price does not reflect Aetna's solid MCO business and the long-term value of a care delivery strategy at retail. Further, he thinks the current valuation already reflects potential shock to PBM margins and future deterioration in the retail business.
SNSS Sunesis
$1.02

-0.17 (-14.29%)

12/20/18
HCWC
12/20/18
INITIATION
Target $0.5
HCWC
Neutral
Sunesis initiated with a Neutral at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Sunesis Pharmaceuticals with a Neutral rating and 50c price target. The analyst prefers to wait for additional clarity on vecabrutinib's potential before recommending the shares.
AIPT Precision Therapeutics
$0.76

-0.0414 (-5.16%)

CHRS Coherus Biosciences
$13.51

-0.59 (-4.18%)

05/14/18
MAXM
05/14/18
NO CHANGE
Target $22
MAXM
Buy
Coherus Biosciences price target raised to $22 from $18 at Maxim
Maxim analyst Jason McCarthy raised his price target on Coherus Biosciences to $22 from $18 after the company announced that the FDA has accepted for review the recently re-submitted BLA for CHS-1701, a biosimilar version of Neulasta. The BSUFA date for a decision is November 3, he noted. The analyst keeps his Buy rating on Coherus Biosciences shares.
06/05/18
MSCO
06/05/18
NO CHANGE
Target $50
MSCO
Overweight
Neulasta biosimilar could 'reignite' Mylan momentum, says Morgan Stanley
Morgan Stanley analyst David Risinger said FDA approval of Fulphila, Mylan's (MYL) biosimilar to Amgen's (AMGN) Neulasta, should be a "substantial and durable" profit opportunity and could "reignite" Mylan's upward momentum. He notes that Mylan anticipates launching Fulphila in the coming weeks and that the FDA biosimilar user fee act action date for Coherus' (CHRS) Neulasta biosimilar is November 3. Risinger has an Overweight rating and $50 price target on Mylan shares.
07/27/18
SBSH
07/27/18
NO CHANGE
Target $25
SBSH
Buy
Citi sees Coherus trading to $21-$25 on today's EMA decision
The European Medicines Agency this morning provided a positive opinion on Coherus Biosciences' version of Neulasta, Citi analyst Mohit Bansal tells investors in a research note. This is positive news as it "significantly lowers" regulatory risk for Neulasta in the U.S. as well, Bansal tells investors in a research note. He notes that while the applicant name is not Coherus on the two applications receiving positive opinions today, the drug name trademark "Udenyca" is registered under Coherus and it seems a third party filed the application on Coherus' behalf. The analyst sees the stock trading in the $21-$25 range on the news. He keeps a Buy rating on Coherus Biosciences with a $25 price target. The stock in premarket trading is up 8%, or $1.40, to $19.75.
08/28/18
HCWC
08/28/18
INITIATION
Target $28
HCWC
Buy
Coherus Biosciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started Coherus Biosciences (CHRS) with a Buy rating and $28 price target. The analyst expects approval of the company's Udencya in both the U.S. and Europe this year. His confidence level is driven by a positive recommendation from the European Committee for Medicinal Products for Human Use in July for marketing authorization of Udencya, a biosimilar compound targeting febrile neutropenia. Coherus announced that the committee reviewed all the new immunogenicity data that were required for the U.S. re-submission too, so the EU recommendation for approval adds a measure of confidence in support of U.S. approval, Kolbert tells investors in a research note. A year-end approval should position Udencya as the second biosimilar in the $4B U.S. marketplace behind Mylan (MYL), which should be launching its product following approval in June, the analyst adds.
CELG Celgene
$88.78

-0.42 (-0.47%)

03/13/19
BARD
03/13/19
NO CHANGE
Target $101
BARD
Outperform
Celgene 'still looks like best option' for Bristol-Myers, says Baird
Baird analyst Brian Skorney notes that on Tuesday, Bristol-Myers (BMY) CEO Giovanni Caforio, speaking at an investor conference, said the company has not had any serious suitors for the company and has not held talks since 2017, when there were no formal offers. In a research note to investors, Skorney says this commentary should help reframe investor expectations as far as what other options Bristol-Myers could explore should the Celgene (CELG) deal fall through, but says Celgene "still looks like the best option." Skorney has an Outperform rating and $101 price target on Celgene.
03/20/19
BMOC
03/20/19
NO CHANGE
Target $62
BMOC
Outperform
Bristol-Myers price target raised to $62 from $59 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Bristol-Myers (BMY) to $62 and kept his Outperform rating, saying its proposed Celgene (CELG) merger is the "right step at the right time." The analyst contends that the company needs to diversify its offerings because of the volatility in immuno-oncology and also boost its long term growth prospects because of the loss of exclusivity for its Eliquis and Opdivo products. Arfaei believes that the combined company will be "meaningfully more diversified and in a better position to fill patent cliffs during 2025-2030" period.
03/21/19
BARD
03/21/19
NO CHANGE
Target $250
BARD
Neutral
Biogen 'hate selling' could bring shares to low $200s, says Baird
Baird analyst Brian Skorney lowered his price target for Biogen (BIIB) to $250 from $348 on the failure of aducanumab in Alzheimer's disease. The analyst feels the big question now is, "where is the backstop?" Biogen without the upside potential of Alzheimer's looks a lot like Celgene (CELG) circa 2018, Skorney tells investors in a research note. He thinks investors "will have a hard time seeing anything but risk." The analyst maintains a Neutral rating on Biogen. However, he sees a potential scenario where "hate selling leads to an attractive entry point in the low $200s." The stock in premarket trading s down 27%, or $86.79, to $233.80. Biogen shares "become buyable" in the low $200s, where the company could attract potential suitors, says Skorney.
03/01/19
CANT
03/01/19
NO CHANGE
Target $100
CANT
Overweight
Celgene trading well below standalone company value, says Cantor Fitzgerald
Despite concerns about the Bristol-Myers (BMY) buyout deal closing in Q3, Celgene (CELG) at these levels is trading well below its value as a standalone company, Cantor Fitzgerald analyst Alethia Young tells investors in a research note. The analyst sees potential upside long-term for an independent Celgene, but views the deal closing as a positive for shareholders "after a volatile 18 months." She reiterates an Overweight rating on Celgene with a $100 price target. If the deal falls through, Young expects downside of $20 per share back to pre-deal announcement levels. However, she thinks there is more value to Celgene shares over time if the company remains independent.
WTKWY Wolters Kluwer
$0.00

(0.00%)

TODAY'S FREE FLY STORIES

11:00
12/13/19
12/13
11:00
12/13/19
11:00
General news
Today's U.S. reports »

Today's U.S. reports…

GPS

Gap

$16.66

-0.36 (-2.12%)

10:55
12/13/19
12/13
10:55
12/13/19
10:55
Options
Gap put volume heavy and directionally bearish »

Bearish flow noted in Gap…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
12/13/19
12/13
10:55
12/13/19
10:55
Conference/Events
Federal Reserve Bank of New York president participates in a discussion »

New York Federal Reserve…

SPT

Sprout Social

$0.00

(0.00%)

10:52
12/13/19
12/13
10:52
12/13/19
10:52
Syndicate
Sprout Social indicated to open at $19.25, IPO priced at $17.00 »

Sprout Social (SPT)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$317.49

0.35 (0.11%)

10:47
12/13/19
12/13
10:47
12/13/19
10:47
General news
U.S. Trade Representative says Phase One trade deal with China 'enforceable' »

United States Trade…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$317.49

0.35 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$286.83

3.03 (1.07%)

10:45
12/13/19
12/13
10:45
12/13/19
10:45
Options
UnitedHealth call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:45
12/13/19
12/13
10:45
12/13/19
10:45
General news
Breaking General news story  »

New York Federal Reserve…

10:45
12/13/19
12/13
10:45
12/13/19
10:45
General news
Breaking General news story  »

New York Federal Reserve…

ALG

Alamo Group

$117.70

0.51 (0.44%)

10:43
12/13/19
12/13
10:43
12/13/19
10:43
Conference/Events
Alamo Group management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

ABT

Abbott

$86.48

0.5 (0.58%)

10:40
12/13/19
12/13
10:40
12/13/19
10:40
Hot Stocks
Abbott raises quarterly dividend 12.5% to 36c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPO

Exponent

$65.46

-0.62 (-0.94%)

10:37
12/13/19
12/13
10:37
12/13/19
10:37
Conference/Events
Exponent management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FLWS

1-800-Flowers.com

$13.56

0.29 (2.19%)

10:35
12/13/19
12/13
10:35
12/13/19
10:35
Conference/Events
1-800-Flowers.com management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

FFIV

F5 Networks

$142.79

-0.84 (-0.58%)

10:35
12/13/19
12/13
10:35
12/13/19
10:35
Periodicals
Police raid Moscow office of F5 Networks' NGINX, ZDNet reports »

On Thursday, police…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPPI

Spectrum

$8.89

0.21 (2.42%)

10:35
12/13/19
12/13
10:35
12/13/19
10:35
Options
Spectrum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$133.61

33.22 (33.09%)

10:34
12/13/19
12/13
10:34
12/13/19
10:34
On The Fly
Sarepta jumps as analysts react to 'surprise' FDA reversal on Vyondys53 »

Shares of Sarepta…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$17.02

(0.00%)

10:32
12/13/19
12/13
10:32
12/13/19
10:32
Hot Stocks
Gap's Old Navy unit teams up with Postmates for on-demand gift delivery »

Gap's Old Navy unit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
12/13/19
12/13
10:30
12/13/19
10:30
General news
Treasury Action: yields remain lower, led by the front end, amid a lack of clarity »

Treasury Action: yields…

10:30
12/13/19
12/13
10:30
12/13/19
10:30
General news
The October U.S. business inventory report tracked estimates »

The October U.S. business…

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$317.78

0.64 (0.20%)

10:29
12/13/19
12/13
10:29
12/13/19
10:29
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says Phase Two…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$317.78

0.64 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$318.00

0.86 (0.27%)

10:29
12/13/19
12/13
10:29
12/13/19
10:29
General news
Breaking General news story on S&P 500, SPDR S&P 500 ETF Trust »

Trump says 25% tariffs on…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$318.00

0.86 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$318.23

1.09 (0.34%)

10:27
12/13/19
12/13
10:27
12/13/19
10:27
General news
Trump says Dec. 15 tariffs will not be charged due to phase one deal »

President Trump just…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$318.23

1.09 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$23.91

0.91 (3.96%)

10:25
12/13/19
12/13
10:25
12/13/19
10:25
Options
Amarin call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Dec

MSFT

Microsoft

$154.18

0.95 (0.62%)

10:25
12/13/19
12/13
10:25
12/13/19
10:25
Hot Stocks
Microsoft unveils Xbox Series X, available Holiday 2020 »

Microsoft announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
12/13/19
12/13
10:25
12/13/19
10:25
General news
FX Action: USD-JPY »

FX Action: USD-JPY is…

10:25
12/13/19
12/13
10:25
12/13/19
10:25
Conference/Events
JPMorgan media analyst to hold an analyst/industry conference call »

Media Analyst Quadrani…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.